GeneDx
WGS · NASDAQ
Bulios Fair Price
$80.36
20.5% downside
Current Price
$101.1
According to Bulios Fair Price, WGS is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
GeneDx is a biotechnology company specializing in genomic testing, particularly exome and genome sequencing, aimed at diagnosing rare and ultra-rare genetic disorders. Founded in 2000, the company is headquartered in Gaithersburg, Maryland. In 2021, GeneDx merged with Sema4 Holdings, strengthening its position in genomic testing. In 2024, the company achieved a significant financial turnaround, reporting its first adjusted net income in the third quarter and a year-over-year revenue increase of 52% to $76.6 million. GeneDx's shares are traded on NASDAQ under the symbol WGS.
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Katherine A. Stueland
Employees
1,300
Headquarters
Stamford
Upcoming events
Earnings
Upcoming earnings report